Thursday, October 15, 2026

DAX Bearish Momentum: 1.1% Down Since The Last Session

ViaNews Editorial Team

January 15, 2021

DAX Bearish Momentum: 1.1% Down Since The Last Session

DAX is currently on bearish momentum. At 07:30 EST on Friday, 15 January, DAX is at €13,834.92, 1.1% down since the last session's close.

DAX Range

DAX is 0.774% down from its last session low of €13,942.90 and 1.392% down from its last session high of €14,030.20.

Over the last three sessions, DAX's higher value was €14,030.20 and the lower value was €13,868.80.

Over the last seven sessions, DAX's higher value was €14,131.50 and the lower value was €13,617.10.

Over the last month, DAX's higher value was €14,131.50 and the lower value was €13,009.50.

Concerning DAX's yearly highs and lows, it's 67.581% up from its 52-week low and 2.099% down from its 52-week high.

Volatility

DAX's last day, last week, and last month's average volatility was 0.35%, 0.03%, and 0.24%, respectively.

DAX's last day, last week, and last month's high and low average amplitude percentage was 0.63%, 0.94%, and 1.19%, respectively.

Last news about DAX

DAX 30 poised to extend climb despite threat of extended restrictions. According to DailyFX on Thursday, 14 January, "We typically take a contrarian view to crowd sentiment, and the fact traders are net-short suggests DAX 30 prices may continue to rise.", "Nevertheless, a degree of caution should be maintained in the near term as the reality of a prolonged period of harsh curbs may begin to gnaw at risk appetite and in turn weigh on Germany's benchmark DAX 30 index."

DAX falls on virus worries. According to Business Insider on Friday, 15 January, "The benchmark DAX dropped 36 points, or 0.3 percent, to 13,952 after rising 0.4 percent the previous day."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com